Related Experiment Video

Updated: Oct 5, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Loss of RPS27a expression regulates the cell cycle, apoptosis, and proliferation via the RPL11-MDM2-p53 pathway in

Hongyan Li1,2,3,4,5,6, Hong Zhang7,8,9,10,11,12, Guomin Huang1,3,4,5,6,13

  • 1Department of Medical Physics, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730000, China.

Journal of Experimental & Clinical Cancer Research : CR
|January 25, 2022
PubMed
Abstract

Insights

Ribosomal protein S27a (RPS27a) binds ribosomal protein L11 (RPL11), inhibiting p53 degradation in lung adenocarcinoma. RPS27a knockdown suppresses tumor growth, suggesting it as a potential therapeutic target.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Ribosomal proteins (RPs) can activate p53, particularly ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11).
  • Understanding the link between RPs and p53 activation is crucial for cancer research.

Purpose of the Study:

  • To investigate the interaction between ribosomal proteins and RPL11.
  • To determine the role of ribosomal protein S27a (RPS27a) in p53 activation within lung adenocarcinoma (LUAD) cells.

Main Methods:

  • Proteomics and immunoprecipitation to identify RPL11-binding proteins.
  • GST pull-down and co-immunoprecipitation assays to analyze protein interactions.
  • In vitro ubiquitination, cell cycle, apoptosis, invasion, migration, viability, and colony formation assays to assess functional effects.
  • TCGA dataset analysis and immunohistochemistry to evaluate RPS27a expression in LUAD.

Main Results:

  • RPS27a was identified as a novel RPL11-binding protein, directly interacting with RPL11.
  • RPS27a knockdown enhanced RPL11-MDM2 binding, inhibiting MDM2-mediated p53 ubiquitination and degradation, thus stabilizing p53.
  • RPS27a upregulation in LUAD correlated with tumor progression, poorer prognosis, and elevated p53, MDM2, and RPL11 levels. RPS27a knockdown suppressed tumor xenograft formation.

Conclusions:

  • RPS27a interacts with RPL11 and modulates p53 stability by affecting MDM2-mediated degradation.
  • RPS27a plays a significant role in LUAD progression and prognosis.
  • RPS27a represents a potential therapeutic target for lung adenocarcinoma.
Keywords:
ApoptosisLung adenocarcinomaRibosomal protein S27a (RPS27a)

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

562
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K